Latest news with #BauschHealth
Yahoo
11 hours ago
- Business
- Yahoo
Bausch Health (BHC) Rebounds 15.8% on Bargain-Hunting
We recently published . Bausch Health Companies Inc. (NYSE:BHC) is one of the best-performing stocks on Monday. Bausch Health bounced back by 15.83 percent on Monday to close at $6.66 apiece as investors appeared to have hunted for bargains, having traded below the $6 level for seven days in a row. Monday's share price marked Bausch Health Companies Inc. (NYSE:BHC) first official claw back to the green territory since the start of the month after hovering for most of the trading days below the $5.89 closing price on July 31. It picked up to $5.94 on August 5, but only by a slight 0.85-percent gain from July 31's closing price. Year-to-date, the company's shares were down by 17.4 percent. In recent news, Bausch Health Companies Inc. (NYSE:BHC) expanded its attributable net income by 1,380 percent in the second quarter of the year to $148 million from only $10 million in the same period last year. Revenues also grew by 5 percent to $2.53 billion from $2.4 billion. Copyright: nimon / 123RF Stock Photo For the full-year period, Bausch Health Companies Inc. (NYSE:BHC) raised its revenue guidance to $10 billion to $10.25 billion, as compared with the $9.95 billion to $10.2 billion previously. While we acknowledge the potential of BHC as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 days ago
- Business
- Yahoo
Bausch Health to Acquire DURECT Corporation in $63M Deal to Advance Liver Disease Treatment
Bausch Health Companies Inc. (NYSE:BHC) is one of the most undervalued Canadian stocks to buy now. On July 29, Bausch Health Companies announced a definitive agreement to acquire DURECT Corporation (NASDAQ:DRRX). The acquisition is valued at ~$63 million upfront with potential for an additional $350 million in sales milestone payments, and will be an all-cash transaction. Bausch Health is acquiring DURECT primarily for its lead asset, called larsucosterol. This novel therapeutic molecule is an epigenetic modulator that the FDA has granted Breakthrough Therapy Designation for the treatment of alcoholic hepatitis/AH, which is a life-threatening form of alcohol-associated liver disease. A closeup of pills in a pharmacy, representing the high quality medications of the company. AH is characterized by severe liver inflammation & necrosis and accounted for ~164,000 hospital admissions in the US in 2021. There are currently no FDA or European Medicines Agency/EMA-approved treatments for the condition. The acquisition of larsucosterol strengthens Bausch Health's commitment to hepatology. Bausch Health plans to use its expertise to advance larsucosterol through a planned Phase 3 program. Bausch Health Companies Inc. (NYSE:BHC) is a diversified specialty pharmaceutical and medical device company that develops, manufactures, and markets products in gastroenterology, hepatology, neurology, dermatology, generic pharmaceuticals, OTC products, aesthetic medical devices, and eye health. DURECT Corporation (NASDAQ:DRRX) is a late-stage biopharmaceutical company that develops epigenetic therapies that target dysregulated DNA methylation to transform the treatment of serious and life-threatening conditions, such as acute organ injury. While we acknowledge the potential of BHC as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
6 days ago
- Business
- Yahoo
Bausch Health Announces 2025 Gastrointestinal Health Scholars Program Winners
For the Sixth Consecutive Year, 10 Students with Gastrointestinal Disease Will Each Receive a $10,000 Scholarship LAVAL, QC / / August 7, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), today announced the recipients of its 2025 Salix Gastrointestinal Health Scholars Program. For the sixth year, Bausch Health is proud to award 10 deserving students living with a GI disease $10,000 each to further their higher education. "The overwhelming response to our scholarship program reflects the unwavering drive and determination of students within the GI community. These remarkable individuals refuse to let their illness define their path," said Aimee Lenar, Executive Vice President, US Pharma, Bausch Health. "Each year, we are inspired by their stories of resilience, which serve as powerful reminders of true strength. Bausch Health is proud to continue providing meaningful financial support to help ease their burden and empower their academic success." The 2025 scholarship recipients were chosen from a competitive pool of over 370 applicants. As part of the selection process, candidates submitted personal essays detailing how their gastrointestinal condition has shaped their educational journey and highlighting the support provided by their health care providers in helping them achieve their academic and personal milestones. All applications were thoroughly evaluated by an independent panel of judges. The program recognizes students across a wide range of educational pursuits, with scholarships in three categories, including the Undergraduate Scholar Awards, for those pursuing undergraduate degrees; the Graduate Scholar Awards, for those pursuing graduate degrees; and the Working and/or Single Parent's Scholar Award, for students who are working and/or single parents pursuing undergraduate, vocational/technical, or graduate degrees. This year's recipients shared powerful reflections on what Bausch Health's Salix Gastrointestinal Health Scholars Award means to them and how it's helping shape their academic journey. "Although my diagnosis has provided many challenges, it has ultimately fueled my desire to become a physician. I have found a passion for helping others, and I plan to become a pediatric gastroenterologist," said Alexis Weary, a scholarship recipient. "I truly appreciate the company for their work in gastrointestinal healthcare and for providing me with this scholarship to help me turn my dreams into a reality." Another scholarship recipient, Samantha Smith said, "This scholarship affirms my belief that chronic illness can be a source of resilience and innovation. I'm deeply grateful to Bausch Health's Salix Gastrointestinal Health Scholars Program for empowering me to continue advocating for inclusive policy reformation." Their words reflect the heart of the program-empowering students to pursue their goals with confidence, support, and pride. Bausch Health's 2025 Salix Gastrointestinal Health Scholars Program recipients are: Undergraduate Scholar Awards Krish Desai - University of California Los Angeles (UCLA) Maya Fischler - Brown University Annie Jones - Colorado State University Ethan Leicht - Louisville State University Maggie Schaefer - Creighton University Keaton Van Nostrand - Florida State University Graduate Scholar Awards Kunika Chahal - SUNY Downstate College of Medicine Samantha Smith - Harvard Business School Alexis Weary - Nova Southeastern University College of Osteopathic Medicine Working and/or Single Parent's Scholar Award Miriam McCarter - Brigham Young University Law School To learn more about Bausch Health's Salix Gastrointestinal Health Scholars Program, visit or visit About Bausch Health Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is a global, diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neurology, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb Corporation. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors. Our gastroenterology business, Salix Pharmaceuticals, is one of the largest specialty pharmaceutical businesses in the world and has licensed, developed and marketed innovative products for the treatment of gastrointestinal diseases for more than 30 years. For more information about Salix, visit and connect with us on Twitter and LinkedIn. For more information about Bausch Health, visit and connect with us on LinkedIn. Investor Contact: Media Contact: Garen Sarafian Katie Savastano ir@ 877-281-6642 (toll-free) 908-569-3692 SOURCE: Bausch Health Companies Inc. View the original press release on ACCESS Newswire
01-08-2025
- Business
Could U.S. tariffs drive up drug prices? Manitoba bioscience group says it's complicated, but possible
Medicine manufacturers across Canada are on edge with the looming threat of catastrophic tariffs on pharmaceutical exports to the U.S., experts say. Earlier this month, U.S. President Donald Trump threatened to impose tariffs as high as 200 per cent on pharmaceuticals exported to the United States. Howard Lutnick, Trump's secretary of commerce, said details about the pharmaceutical tariffs would come at the end of July. The uncertainty this created is starting to reveal itself as stock prices of major pharmaceutical manufacturing companies with operations in Canada — companies like Emergent Biosolutions and Bausch Health — have declined in recent days. If a 200 per cent tariff were to be put into place then I think [pharmaceutical manufacturers] would have to potentially reconsider whether it makes sense to manufacture in Canada, says Shawn Bugden, dean of the school of pharmacy at Memorial University. So what could the impact be in Canada? Given the tariff uncertainty, it's intensely complicated, says Bugden. According to government data, the pharmaceutical industry in Canada represents two per cent (new window) of global market share, and the manufacturing portion of it alone consists of an average of 35,000 jobs since 2019. Enlarge image (new window) Andrea Ladouceur, president and chief executive officer of the Bioscience Association of Manitoba, describes the pharmaceutical industry as the cornerstone of the province's economy. Photo: CBC / Justin Fraser In Manitoba, medicine is one of the leading industries, accounting for between 30-35 per cent of the medicine manufactured in Canada, seven per cent of the province's GDP, and roughly 14,000 jobs, according to Andrea Ladouceur, president of the Bioscience Association of Manitoba. The pharmaceutical industry is the cornerstone of the Manitoba economy, said Ladouceur. If being in Canada becomes unaffordable for them, these companies are connected to the global market and moving out of Canada is not off the table. The danger of these companies leaving is multifaceted. Not only would there be the major economic impact of a shrinking key industry, but we'd also lose the security of having some of the drug supply manufactured here in Canada, according to Bugden. The reliance on international trade for essential goods like medicines has proved risky in the past. During the COVID-19 pandemic, drug shortages (new window) in Canada were not uncommon. If pharmaceutical manufacturers move operations out of the country, it will likely make Canada even more reliant on global markets than they already are: with 70 per cent of drugs imported from foreign countries, 16 per cent of which is imported from the U.S., accounting for nearly $9 billion, according to Bugden. However, Budgen's main concern is that a sizable tariff, like the 200 per cent figure touted by Trump, would undermine Canada's price control mechanisms like the Patented Medicine Prices Review Board and the pan-Canadian Pharmaceutical Alliance — which he views as major assets to Canadians. The Patented Medicine Prices Review Board — established in 1987 but amended in 2019 — is meant to (new window) ensure that the prices of patented medicines sold in Canada are not excessive. The board reviews the price of drugs and medicine and conducts hearings which may result in orders to reduce prices to a non-excessive level, according to guidelines listed on their website. Shawn Bugden, dean of the school of pharmacy at Memorial University, says if Canadian pharmaceutical companies are hurt by tariffs on imports to the U.S., it could have an impact on the supply of some medicines in Canada. Photo: Submitted by Shawn Bugden Bugden says that as an unintended consequence, implementing such a substantial tariff would likely raise the cost of manufacturing drugs and medicine globally, in turn applying pressure on the review board to break their own rules and allow for higher-priced drugs. The Americans have been transparent, they say they have the highest drug prices in the world, we want to lower them, but we're not going to lower them, which is what they should do and they have the ability to do, we're instead going to try and make everybody else pay higher prices so that it allows our prices to go down, said Bugden. As things stand, many pharmaceutical companies are waiting to see what will happen. CBC News has reached out to several pharmaceutical companies in Manitoba, but none have wanted to comment given the uncertainty of the situation they're facing. Ladouceur says they're fearful that tariffs may force them to increase their prices. At the end of the day, any increase in cost will be passed on to the consumer, says Ladouceur. And so for these companies it is a very hard spot because they know it may put them out of reach for the consumer, and having medicines are key to having a healthy life and sometimes save a life, so they are really concerned their products will become unaffordable for those that need them most. Trump has said that there would be a period — a year, or a year and a half after a tariff would be imposed for companies to get their act together. In light of that, Bugden doesn't think the end consumer will be paying the price for at least a year. I don't think consumers need to worry about the prices changing tomorrow, said Bugden. Keep calm and carry on, don't think you need to run to the drug store and fill up your prescriptions. I'm confident in the institutions we have in Canada to do the best job possible to maintain pricing and accessibility for Canadians, said Bugden.
Yahoo
31-07-2025
- Business
- Yahoo
Bausch Health (BHC) Lags Q2 Earnings Estimates
Bausch Health (BHC) came out with quarterly earnings of $0.9 per share, missing the Zacks Consensus Estimate of $0.97 per share. This compares to earnings of $0.89 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -7.22%. A quarter ago, it was expected that this drugmaker would post earnings of $0.83 per share when it actually produced earnings of $0.59, delivering a surprise of -28.92%. Over the last four quarters, the company has surpassed consensus EPS estimates two times. Bausch, which belongs to the Zacks Medical - Generic Drugs industry, posted revenues of $2.53 billion for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 2.42%. This compares to year-ago revenues of $2.4 billion. The company has topped consensus revenue estimates three times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Bausch shares have lost about 15.4% since the beginning of the year versus the S&P 500's gain of 8.3%. What's Next for Bausch? While Bausch has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Bausch was favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $1.13 on $2.57 billion in revenues for the coming quarter and $3.96 on $10 billion in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Generic Drugs is currently in the top 37% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Amphastar Pharmaceuticals (AMPH), another stock in the same industry, has yet to report results for the quarter ended June 2025. The results are expected to be released on August 7. This specialty pharmaceutical company is expected to post quarterly earnings of $0.71 per share in its upcoming report, which represents a year-over-year change of -24.5%. The consensus EPS estimate for the quarter has been revised 1.3% higher over the last 30 days to the current level. Amphastar Pharmaceuticals' revenues are expected to be $169.84 million, down 6.9% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Bausch Health Cos Inc. (BHC) : Free Stock Analysis Report Amphastar Pharmaceuticals, Inc. (AMPH) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
